Drug-related overdose deaths in British Columbia and Ontario, 1992-2004

Canadian Journal of Public Health

Volumn 97, Issue 5, 2006, Pages 384-387

  Fischer, Benedikt ^a,b   Popova, Svetlana ^a,b   Rehm, Jürgen ^a,b,c   Ivsins, Andrew ^a  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c Institut fur Sucht und Gesundheitsforschung Zurich   (Switzerland)

Author keywords

Canada; Mortality; Overdose; Public policy; Street drugs

Indexed keywords

ILLICIT DRUG;

ARTICLE; CANADA; DRUG FATALITY; DRUG OVERDOSE; EVIDENCE BASED PRACTICE; HUMAN; INCIDENCE; MONITORING; MORTALITY; POLICY; STATISTICAL SIGNIFICANCE; SUBSTANCE ABUSE;

EID: 33750367575     PISSN: 00084263     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf03405347     Document Type: Article

References (31)

1. English D, Holman C, Milne E, Winter M, Hulse G, Codde G, et al. The quantification of drug caused morbidity in Australia 1995. Canberra, Australia: Commonwealth Department of Human Services and Health, 1995.
2. Rehm J. Situation sociale des consommateurs de drogues. In: Fahrenkrug H, Müller R, Klingemann H, Linder R (Eds.). Drogues illégales en Suisse 1990-1993. La situation dans les cantons et en Suisse. Zurich, Switzerland: Seismo, 1995;35-54.
3. O'Driscoll PT, McGough J, Hagan H, Thiede H, Critchlow C, Alexander ER. Predictors of accidental fatal drug overdose among a cohort of injection drug users. Am J Public Health 2001;91(6):984-87.
4. Gossop M, Stewart D, Treacy S, Marsden J. A prospective study of mortality among drug misusers during a 4-year period after seeking treatment. Addiction 2002;97:39-47.
5. Fischer B, Rehm J, Blitz-Miller T. Injection drug use and preventive measures: A comparison of Canadian and Western European jurisdiction over time. CMAJ 2000;162:1709-13.
6. Darke S, Hall W. Heroine overdose: Research and evidence-based intervention. J Urban Health 2003;80(2):189-200.
7. European Monitoring Centre for Drugs and Drug Addiction. Annual report on the state of the drugs problem in the European Union and Norway. EMCDDA, 2002.
8. Garfield J, Drucker E. Fatal overdose trends in major US cities: 1990-1997. Addiction Res Theory 2001;9:425-36.
9. Strang J, Griffiths P, Powis B, Gossop M. Heroin chasers and heroin injectors: Differences observed in a community sample in London, UK. Am J Addict 1999;8:148-60.
10. Hembree C, Galea S, Ahern J, Tracy M, Piper TM, Miller J, et al. The urban built environment and overdose mortality in New York City neighborhoods. Health Place 2005;11(2):147-56.
11. Coffin P, Galea S, Ahern J, Leon A, Vlahov D, Tardiff K. Opiates, cocaine and alcohol combinations in accidental drug overdose deaths in New York City, 1990-98. Addiction 2003;98:739-47.
12. Fischer B, Brissette S, Brochu S, Bruneau J, el-Guebaly N, Noel L, et al. Prevalence and determinants of overdose incidents among illicit opioid users in five cities across Canada. CMAJ 2004;171:235-39.
13. Ghodse M, Sheehan M, Taylor C, Edwards G. Death of drug addicts in the United Kingdom. Br Med J 1985;290:425-29.
14. Ward J, Hall W, Mattick RP. Role of maintenance treatment in opioid dependence. Lancet 1999;353(9148):221-26.
15. F/P/T Advisory Committee on Population Health. Reducing the Harm Associated with Injection Drug Use in Canada. Health Canada, 2001.
16. Cain V. Report of the Task Force into Illicit Narcotic Overdose Deaths in British Columbia. Burnaby, BC: Office of the Chief Coroner, Province of British Columbia, 1994.
17. Buxton J. Vancouver Drug Use Epidemiology. Report. Vancouver, BC: Canadian Community Epidemiology Network on Drug Use, 2003.
18. Fischer B, Rehm J, Brissette S, Brochu S, Bruneau J, el-Guebaly N, et al. Illicit opioid users in Canada: Comparing social, health and drug use characteristics of untreated users in five cities (OPICAN study). J Urban Health 2005;82(2):250-66.
19. Haydon E, Fischer B. Crack use as a public health problem in Canada: Call for an evaluation of "safer crack use kits." Can J Public Health 2005;96(3):185-88.
20. Substance Use in Toronto: Issues, Impacts and Interventions. An environmental scan prepared for the Toronto Drug Strategy Initiative. Toronto, ON: City of Toronto, 2005.
21. Preventing Harm from Psychoactive Substance Use. Report. Vancouver: City of Vancouver, 2005.
22. Single E, Robson L, Xie X, Rehm J. The cost of substance abuse in Canada. Ottawa: Canadian Centre on Substance Abuse, 1996.
23. Popova S, Rehm J, Fischer B. An overview of illegal opioid use and health services utilization in Canada. Public Health 2006;120:320-28.
24. Anderson J, Warren L. Client retention in the British Columbia methadone program, 1996-1999. Can J Public Health 2004;95(2):104-9.
25. MacPherson D. A Framework for Action: A four-pillar approach to drug problems in Vancouver. City of Vancouver, 2001.
26. Fischer B. Prescriptions, power and politics: The turbulent history of methadone maintenance treatment in Canada. J Public Health Policy 2000;21(2):187-210.
27. Brands B, Blake J, Marsh D. Changing patient characteristics with increased methadone maintenance availability. Drug Alcohol Depend 2002;66(1):11-20.
28. Strike CJ, Urbanoski K, Fischer B, March DC, Margaret M. Policy changes and the methadone maintenance treatment system for opioid dependence in Ontario, 1996 to 2001. J Addict Dis 2005;24(1):39-51.
29. Sibbald B. Tighten Ontario's methadone program states inquest. CMAJ 2005;172(3):319-20.
30. Wood E, Kerr T, Montaner JS, Strathdee SA, Wodak A. Rationale for evaluating North America's first medically supervised safer-injecting facility. Lancet Infect Dis 2004;4(5):301-6.
31. Schechter MT. NAOMI-her time has come. North American Opiate Medication Initiative. J Urban Health 2002;79(2):164-65.